February 6, 2019 08:22 AM EST
Pharma

Capri­cor to re­sume dos­ing in DMD tri­al — but scarce re­sources force com­pa­ny to pause en­roll­ment, cut jobs

Natalie Grover

Reporter

Lit­tle Capri­cor $CAPR is do­ing its best to lim­it the dam­age of its big prob­lems. On Wednes­day, the com­pa­ny said it is ex­plor­ing strate­gic al­ter­na­tives …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

A service from the Financial Times